Hook & thesis
Indivior punched above expectations for FY25 and followed with a practical capital markets move: an upsized $450 million convertible note offering on 03/13/2026 that will be used largely to pay down term debt and repurchase shares. The near-term headline - added convertible debt - spooked some traders, but beneath that noise the core thesis is intact: SUBLOCADE remains the revenue engine and management is deploying proceeds to reduce cash-costly bank borrowings and return capital to shareholders.
My trade idea: buy Indivior now at $28.82 with a targeted exit near the pre-December highs, and a stop that limits downside if SUBLOCADE momentum slows or the convertible issuance creates unexpected dilution. This is a long-term tactical trade - long term (180 trading days) - sized for a medium-risk allocation.
Business snapshot - why the market should care
Indivior is focused on treatments for opioid use disorder (OUD), with a single-product revenue profile dominated by SUBLOCADE. Management expects total net revenue for 2026 of $1,125 - $1,195 million and SUBLOCADE net revenue of $905 - $945 million, which highlights how concentrated the business remains. The market for evidence-based OUD therapies has favorable secular tailwinds: increasing diagnosis, expanded payer coverage, and ongoing policy attention to addiction treatment.
At a macro level, investors care because Indivior pairs a resilient revenue stream with improving capital structure dynamics. The convertible notes priced on 03/13/2026 - $450 million at 0.625% due 2031 and a conversion price near $41.66 (about 35% premium to current levels) - are explicitly earmarked to repay $239 million of existing debt and repurchase roughly 2.4 million shares ($75 million). That trade-off (modest additional convert debt vs. immediate reduction in bank leverage and share count) is a classic restructuring that can improve interest costs and free cash flow once executed.
What the numbers say
| Metric | Value |
|---|---|
| Current price | $28.82 |
| Market cap | $3.60B |
| 2026 revenue guidance | $1,125 - $1,195M |
| SUBLOCADE 2026 guidance | $905 - $945M |
| EPS (trailing) | $1.71 |
| P/E | ~17.7x |
| EV / EBITDA | ~13.3x |
| Free cash flow (latest) | -$93M |
| 52-week range | $8.64 - $38.00 |
| Float | ~120.7M shares |
The valuation is reasonable for a specialty pharma name with a dominant product. At a market cap near $3.6 billion and implied revenue roughly consistent with a $1.15B top line, the price-to-sales (~2.85x reported) and P/E near the high-teens reflect both durable revenue and lingering execution risk. EV/EBITDA of 13.3x isn't cheap, but it is defensible for a company with a clear core product and improving cost structure post-debt reduction.
Technicals & positioning
Technically, INDV is showing short-term weakness - SMA and EMA series are trending lower and MACD registers bearish momentum - yet RSI is around 34.6, which is close to oversold. Short interest is non-trivial: recent settlement data (03/13/2026) shows ~12.19M shares short, or roughly 10% of the float. High short interest has been paired with heavy short volume days in late March, suggesting elevated volatility and the potential for quick moves if product momentum or capital structure news surprises to the upside.
Catalysts (what will drive the trade)
- Execution against 2026 guidance - SUBLOCADE net revenue hitting the $905 - $945M range would validate demand and pricing trends.
- Successful close and execution of the $450M convertible on 03/13/2026 - reduction in bank debt and completion of the announced $75M buyback will materially improve interest expense and financial flexibility.
- Favorable clinical or policy developments that increase access or coverage for OUD treatments.
- Quarterly results that show margin expansion or approaching free cash flow breakeven after debt paydown.
Trade plan - actionable with horizon and reasons
Trade direction: Long.
Entry: $28.82. This is effectively buying at the current market level where the convertible paperwork is priced in and SUBLOCADE guidance is known.
Target: $36.00. This target sits below the 52-week high of $38.00 and represents a realistic re-rating if SUBLOCADE growth matches guidance and leverage is reduced — about a ~25% upside from entry.
Stop loss: $25.50. A drop below $25.50 would indicate that the market is discounting continued SUBLOCADE deterioration or a negative reaction to the convertible execution (unexpected dilution or covenant issues).
Horizon: long term (180 trading days). Rationale: the convertible close and its impact on interest expense and share count will play out over multiple quarters; SUBLOCADE adoption and payer dynamics are medium-term processes. Give the name several quarters for revenue and cash flow improvement to materialize.
Position sizing & risk management
This is a medium-risk trade. Use position sizing to limit portfolio exposure so a stop loss represents a tolerable drawdown. Because short interest is elevated, expect sharper intraday moves and set alerts for spikes in volume or swings driven by short-covering.
Risks and counterarguments
- Concentration risk: Indivior is heavily dependent on SUBLOCADE. If competition intensifies or payer access weakens, revenue could fall short of guidance.
- Capital structure & dilution: The convertible note, while low-coupon, can lead to equity dilution if the share price approaches the $41.66 conversion price; although conversion is remote at current levels, future accounting and perception issues can weigh on the stock.
- Cash flow pressure: Latest reported free cash flow is negative (-$93M). If operating cash flow does not improve, the company may need additional financing or be forced into cost cuts that impair growth.
- Regulatory & legal risk: Pharmaceuticals with opioid-focused products face ongoing scrutiny and potential litigation or policy changes that can impact prescribing patterns.
- Technical downside and short squeeze flip: Elevated short interest can work both ways. A sell-off can be amplified by short sellers, and conversely, a squeeze could dramatically overshoot targets; either outcome increases volatility and execution risk.
Counterargument: A reasonable view is that the convertible upsizing simply reflects a need to refinance on unattractive terms and the market is right to be cautious. SUBLOCADE's growth has shown sensitivity to competition historically - management cut FY24 guidance in 10/10/2024 when competitive pressure emerged - and the stock's mid-teens P/E already prices in limited upside. If SUBLOCADE slows or payers push back, the convertible could be seen as a band-aid that postpones a tougher restructuring.
What would change my mind?
I would downgrade this idea if: 1) SUBLOCADE quarterly trends miss guidance meaningfully for two consecutive quarters; 2) free cash flow continues negative with rising receivables, signaling structural demand weakness; or 3) the convertible issuance reveals covenants or contingencies that materially change the capital structure beyond the stated objectives. Conversely, I would become more bullish if management reports sequential margin improvement, paydown of bank debt is completed, and SUBLOCADE shows steady share gains with payer wins.
Conclusion
Indivior is an asymmetric, tactical long here: a focused product franchise with clear near-term levers (SUBLOCADE growth, debt paydown, buybacks) and a valuation that leaves room for re-rating if execution follows through. The $450M convertible is a headline risk, but it also reduces high-cost bank debt and funds buybacks that can support EPS. For disciplined traders who accept medium risk and use the stop laid out above, this is a trade worth taking over the next 180 trading days.
Trade plan recap: Long INDV at $28.82, target $36.00, stop $25.50, horizon long term (180 trading days).